Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lobaplatin + docetaxel versus cisplatin + docetaxel as first-line therapy for advanced lung squamous cell carcinoma
ChiCTR-IPR-17012537Phase 4Not yet recruiting
- Sponsor
- Nanxishan Hospital
- Start
- Oct 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lobaplatin, docetaxel and cisplatin in Pulmonary squamous cell carcinoma, sponsored by Nanxishan Hospital. Planned start Oct 2017; status: not yet recruiting.
02
Drugs
lobaplatindocetaxelcisplatin
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR-IPR-17012537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17012537.